Superior Overall Survival in Patients with Colorectal Cancer, Regular Aspirin Use, and Combined Wild-Type PIK3CA and KRAS-Mutated Tumors

The impact of aspirin use after the diagnosis of colorectal cancer is unknown. Among others, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) mutational status was proposed as a molecular biomarker for the response to adjuvant aspirin therapy. However, prognostic data...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2021-10, Vol.13 (19), p.4959
Main Authors: Gebauer, Leonie, Nist, Andrea, Mernberger, Marco, Stiewe, Thorsten, Moll, Roland, Stabla, Kathleen, Klinge, Uwe, Mack, Elisabeth, Brendel, Cornelia, Neubauer, Andreas
Format: Article
Language:English
Subjects:
Aspirin
Biomarkers
Cancer
Cardiovascular disease
Colorectal cancer
Colorectal carcinoma
Diagnosis
K-Ras protein
Kinases
Medical prognosis
Metastasis
Mutation
Next-generation sequencing
Patients
Phosphatidylinositol 4,5-diphosphate
Primary care
Software
Statistical analysis
Surgery
Survival
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c398t-b6f87973567c0fb0b3f885ed8b11206c3696a89a1af4ba3bae55a09ffdfd7a7f3
cites cdi_FETCH-LOGICAL-c398t-b6f87973567c0fb0b3f885ed8b11206c3696a89a1af4ba3bae55a09ffdfd7a7f3
container_end_page
container_issue 19
container_start_page 4959
container_title Cancers
container_volume 13
creator Gebauer, Leonie
Nist, Andrea
Mernberger, Marco
Stiewe, Thorsten
Moll, Roland
Stabla, Kathleen
Klinge, Uwe
Mack, Elisabeth
Brendel, Cornelia
Neubauer, Andreas
description The impact of aspirin use after the diagnosis of colorectal cancer is unknown. Among others, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) mutational status was proposed as a molecular biomarker for the response to adjuvant aspirin therapy. However, prognostic data on aspirin use after a colorectal cancer diagnosis in relation to KRAS mutational status is limited. In a single-center retrospective study, we obtained KRAS and PIK3CA mutational status in a cohort of 153 patients with a first diagnosis of colorectal cancer receiving tumor surgery with curative intent. PIK3CA mutational status was determined by pyrosequencing, and KRAS mutational status was determined by next-generation sequencing. Clinicopathological data and survival data were assessed using patient records and reporting registers. We observed a significant 10-year overall survival benefit in patients with aspirin use and combined wild-type PIK3CA and mutated-KRAS tumors (HR = 0.38; 95% CI = 0.17–0.87; p = 0.02), but not in patients without aspirin use. Our data indicate a benefit of aspirin usage particularly for patients with combined wild-type PIK3CA and mutated-KRAS tumor characteristics.
doi_str_mv 10.3390/cancers13194959
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8507980</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2580976038</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-b6f87973567c0fb0b3f885ed8b11206c3696a89a1af4ba3bae55a09ffdfd7a7f3</originalsourceid><addsrcrecordid>eNpdkU1LHTEYhUNpUVHX3Qa66cKpyWQmH5vCZbCtqCjeK12GTCbRSGYyTSa3-A_6sxs_kNZ3kxfOk5McDgAfMfpCiEDHWk3axIQJFo1oxTuwVyNWV5SK5v0_-y44TOkelSEEM8p2wC5pKOFNU--BP-s8m-hChJdbE5X3cJ3j1m2Vh26CV2pxZloS_O2WO9gFH6LRS9G6p6eP4LW5zV5FuEqzi-XCTTJHUE1DYcfeTWaAP50fqs3DbODV6RnpVk_q2fVqXV3kRS2F2OQxxHQAPljlkzl8OffBzbeTTfejOr_8ftqtzitNBF-qnlrOBCMtZRrZHvXEct6agfcY14hqQgVVXCisbNMr0ivTtgoJawc7MMUs2Qdfn33n3I9m0CVeiS3n6EYVH2RQTv6vTO5O3oat5C1igqNi8PnFIIZf2aRFji5p472aTMhJ1i3HTAhK24J-eoPehxynEu-RQoJRRHihjp8pHUNK0djXz2AkH4uWb4omfwHnkpzQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2580976038</pqid></control><display><type>article</type><title>Superior Overall Survival in Patients with Colorectal Cancer, Regular Aspirin Use, and Combined Wild-Type PIK3CA and KRAS-Mutated Tumors</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Gebauer, Leonie ; Nist, Andrea ; Mernberger, Marco ; Stiewe, Thorsten ; Moll, Roland ; Stabla, Kathleen ; Klinge, Uwe ; Mack, Elisabeth ; Brendel, Cornelia ; Neubauer, Andreas</creator><creatorcontrib>Gebauer, Leonie ; Nist, Andrea ; Mernberger, Marco ; Stiewe, Thorsten ; Moll, Roland ; Stabla, Kathleen ; Klinge, Uwe ; Mack, Elisabeth ; Brendel, Cornelia ; Neubauer, Andreas</creatorcontrib><description>The impact of aspirin use after the diagnosis of colorectal cancer is unknown. Among others, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) mutational status was proposed as a molecular biomarker for the response to adjuvant aspirin therapy. However, prognostic data on aspirin use after a colorectal cancer diagnosis in relation to KRAS mutational status is limited. In a single-center retrospective study, we obtained KRAS and PIK3CA mutational status in a cohort of 153 patients with a first diagnosis of colorectal cancer receiving tumor surgery with curative intent. PIK3CA mutational status was determined by pyrosequencing, and KRAS mutational status was determined by next-generation sequencing. Clinicopathological data and survival data were assessed using patient records and reporting registers. We observed a significant 10-year overall survival benefit in patients with aspirin use and combined wild-type PIK3CA and mutated-KRAS tumors (HR = 0.38; 95% CI = 0.17–0.87; p = 0.02), but not in patients without aspirin use. Our data indicate a benefit of aspirin usage particularly for patients with combined wild-type PIK3CA and mutated-KRAS tumor characteristics.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers13194959</identifier><identifier>PMID: 34638442</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Aspirin ; Biomarkers ; Cancer ; Cardiovascular disease ; Colorectal cancer ; Colorectal carcinoma ; Diagnosis ; K-Ras protein ; Kinases ; Medical prognosis ; Metastasis ; Mutation ; Next-generation sequencing ; Patients ; Phosphatidylinositol 4,5-diphosphate ; Primary care ; Software ; Statistical analysis ; Surgery ; Survival ; Tumors</subject><ispartof>Cancers, 2021-10, Vol.13 (19), p.4959</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-b6f87973567c0fb0b3f885ed8b11206c3696a89a1af4ba3bae55a09ffdfd7a7f3</citedby><cites>FETCH-LOGICAL-c398t-b6f87973567c0fb0b3f885ed8b11206c3696a89a1af4ba3bae55a09ffdfd7a7f3</cites><orcidid>0000-0003-4061-494X ; 0000-0003-1612-9557 ; 0000-0003-0134-7826 ; 0000-0002-7606-8760</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2580976038/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2580976038?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25728,27898,27899,36986,36987,44563,53763,53765,75093</link.rule.ids></links><search><creatorcontrib>Gebauer, Leonie</creatorcontrib><creatorcontrib>Nist, Andrea</creatorcontrib><creatorcontrib>Mernberger, Marco</creatorcontrib><creatorcontrib>Stiewe, Thorsten</creatorcontrib><creatorcontrib>Moll, Roland</creatorcontrib><creatorcontrib>Stabla, Kathleen</creatorcontrib><creatorcontrib>Klinge, Uwe</creatorcontrib><creatorcontrib>Mack, Elisabeth</creatorcontrib><creatorcontrib>Brendel, Cornelia</creatorcontrib><creatorcontrib>Neubauer, Andreas</creatorcontrib><title>Superior Overall Survival in Patients with Colorectal Cancer, Regular Aspirin Use, and Combined Wild-Type PIK3CA and KRAS-Mutated Tumors</title><title>Cancers</title><description>The impact of aspirin use after the diagnosis of colorectal cancer is unknown. Among others, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) mutational status was proposed as a molecular biomarker for the response to adjuvant aspirin therapy. However, prognostic data on aspirin use after a colorectal cancer diagnosis in relation to KRAS mutational status is limited. In a single-center retrospective study, we obtained KRAS and PIK3CA mutational status in a cohort of 153 patients with a first diagnosis of colorectal cancer receiving tumor surgery with curative intent. PIK3CA mutational status was determined by pyrosequencing, and KRAS mutational status was determined by next-generation sequencing. Clinicopathological data and survival data were assessed using patient records and reporting registers. We observed a significant 10-year overall survival benefit in patients with aspirin use and combined wild-type PIK3CA and mutated-KRAS tumors (HR = 0.38; 95% CI = 0.17–0.87; p = 0.02), but not in patients without aspirin use. Our data indicate a benefit of aspirin usage particularly for patients with combined wild-type PIK3CA and mutated-KRAS tumor characteristics.</description><subject>Aspirin</subject><subject>Biomarkers</subject><subject>Cancer</subject><subject>Cardiovascular disease</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Diagnosis</subject><subject>K-Ras protein</subject><subject>Kinases</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Mutation</subject><subject>Next-generation sequencing</subject><subject>Patients</subject><subject>Phosphatidylinositol 4,5-diphosphate</subject><subject>Primary care</subject><subject>Software</subject><subject>Statistical analysis</subject><subject>Surgery</subject><subject>Survival</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkU1LHTEYhUNpUVHX3Qa66cKpyWQmH5vCZbCtqCjeK12GTCbRSGYyTSa3-A_6sxs_kNZ3kxfOk5McDgAfMfpCiEDHWk3axIQJFo1oxTuwVyNWV5SK5v0_-y44TOkelSEEM8p2wC5pKOFNU--BP-s8m-hChJdbE5X3cJ3j1m2Vh26CV2pxZloS_O2WO9gFH6LRS9G6p6eP4LW5zV5FuEqzi-XCTTJHUE1DYcfeTWaAP50fqs3DbODV6RnpVk_q2fVqXV3kRS2F2OQxxHQAPljlkzl8OffBzbeTTfejOr_8ftqtzitNBF-qnlrOBCMtZRrZHvXEct6agfcY14hqQgVVXCisbNMr0ivTtgoJawc7MMUs2Qdfn33n3I9m0CVeiS3n6EYVH2RQTv6vTO5O3oat5C1igqNi8PnFIIZf2aRFji5p472aTMhJ1i3HTAhK24J-eoPehxynEu-RQoJRRHihjp8pHUNK0djXz2AkH4uWb4omfwHnkpzQ</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Gebauer, Leonie</creator><creator>Nist, Andrea</creator><creator>Mernberger, Marco</creator><creator>Stiewe, Thorsten</creator><creator>Moll, Roland</creator><creator>Stabla, Kathleen</creator><creator>Klinge, Uwe</creator><creator>Mack, Elisabeth</creator><creator>Brendel, Cornelia</creator><creator>Neubauer, Andreas</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PKEHL</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4061-494X</orcidid><orcidid>https://orcid.org/0000-0003-1612-9557</orcidid><orcidid>https://orcid.org/0000-0003-0134-7826</orcidid><orcidid>https://orcid.org/0000-0002-7606-8760</orcidid></search><sort><creationdate>20211001</creationdate><title>Superior Overall Survival in Patients with Colorectal Cancer, Regular Aspirin Use, and Combined Wild-Type PIK3CA and KRAS-Mutated Tumors</title><author>Gebauer, Leonie ; Nist, Andrea ; Mernberger, Marco ; Stiewe, Thorsten ; Moll, Roland ; Stabla, Kathleen ; Klinge, Uwe ; Mack, Elisabeth ; Brendel, Cornelia ; Neubauer, Andreas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-b6f87973567c0fb0b3f885ed8b11206c3696a89a1af4ba3bae55a09ffdfd7a7f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aspirin</topic><topic>Biomarkers</topic><topic>Cancer</topic><topic>Cardiovascular disease</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Diagnosis</topic><topic>K-Ras protein</topic><topic>Kinases</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Mutation</topic><topic>Next-generation sequencing</topic><topic>Patients</topic><topic>Phosphatidylinositol 4,5-diphosphate</topic><topic>Primary care</topic><topic>Software</topic><topic>Statistical analysis</topic><topic>Surgery</topic><topic>Survival</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gebauer, Leonie</creatorcontrib><creatorcontrib>Nist, Andrea</creatorcontrib><creatorcontrib>Mernberger, Marco</creatorcontrib><creatorcontrib>Stiewe, Thorsten</creatorcontrib><creatorcontrib>Moll, Roland</creatorcontrib><creatorcontrib>Stabla, Kathleen</creatorcontrib><creatorcontrib>Klinge, Uwe</creatorcontrib><creatorcontrib>Mack, Elisabeth</creatorcontrib><creatorcontrib>Brendel, Cornelia</creatorcontrib><creatorcontrib>Neubauer, Andreas</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Biological Sciences</collection><collection>ProQuest research library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied &amp; Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gebauer, Leonie</au><au>Nist, Andrea</au><au>Mernberger, Marco</au><au>Stiewe, Thorsten</au><au>Moll, Roland</au><au>Stabla, Kathleen</au><au>Klinge, Uwe</au><au>Mack, Elisabeth</au><au>Brendel, Cornelia</au><au>Neubauer, Andreas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Superior Overall Survival in Patients with Colorectal Cancer, Regular Aspirin Use, and Combined Wild-Type PIK3CA and KRAS-Mutated Tumors</atitle><jtitle>Cancers</jtitle><date>2021-10-01</date><risdate>2021</risdate><volume>13</volume><issue>19</issue><spage>4959</spage><pages>4959-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>The impact of aspirin use after the diagnosis of colorectal cancer is unknown. Among others, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) mutational status was proposed as a molecular biomarker for the response to adjuvant aspirin therapy. However, prognostic data on aspirin use after a colorectal cancer diagnosis in relation to KRAS mutational status is limited. In a single-center retrospective study, we obtained KRAS and PIK3CA mutational status in a cohort of 153 patients with a first diagnosis of colorectal cancer receiving tumor surgery with curative intent. PIK3CA mutational status was determined by pyrosequencing, and KRAS mutational status was determined by next-generation sequencing. Clinicopathological data and survival data were assessed using patient records and reporting registers. We observed a significant 10-year overall survival benefit in patients with aspirin use and combined wild-type PIK3CA and mutated-KRAS tumors (HR = 0.38; 95% CI = 0.17–0.87; p = 0.02), but not in patients without aspirin use. Our data indicate a benefit of aspirin usage particularly for patients with combined wild-type PIK3CA and mutated-KRAS tumor characteristics.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>34638442</pmid><doi>10.3390/cancers13194959</doi><orcidid>https://orcid.org/0000-0003-4061-494X</orcidid><orcidid>https://orcid.org/0000-0003-1612-9557</orcidid><orcidid>https://orcid.org/0000-0003-0134-7826</orcidid><orcidid>https://orcid.org/0000-0002-7606-8760</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2072-6694
ispartof Cancers, 2021-10, Vol.13 (19), p.4959
issn 2072-6694
2072-6694
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8507980
source Publicly Available Content (ProQuest); PubMed Central
subjects Aspirin
Biomarkers
Cancer
Cardiovascular disease
Colorectal cancer
Colorectal carcinoma
Diagnosis
K-Ras protein
Kinases
Medical prognosis
Metastasis
Mutation
Next-generation sequencing
Patients
Phosphatidylinositol 4,5-diphosphate
Primary care
Software
Statistical analysis
Surgery
Survival
Tumors
title Superior Overall Survival in Patients with Colorectal Cancer, Regular Aspirin Use, and Combined Wild-Type PIK3CA and KRAS-Mutated Tumors
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-27T07%3A25%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Superior%20Overall%20Survival%20in%20Patients%20with%20Colorectal%20Cancer,%20Regular%20Aspirin%20Use,%20and%20Combined%20Wild-Type%20PIK3CA%20and%20KRAS-Mutated%20Tumors&rft.jtitle=Cancers&rft.au=Gebauer,%20Leonie&rft.date=2021-10-01&rft.volume=13&rft.issue=19&rft.spage=4959&rft.pages=4959-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers13194959&rft_dat=%3Cproquest_pubme%3E2580976038%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c398t-b6f87973567c0fb0b3f885ed8b11206c3696a89a1af4ba3bae55a09ffdfd7a7f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2580976038&rft_id=info:pmid/34638442&rfr_iscdi=true